Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MILGa-01: A first in human study to evaluate the safety and tolerability of monoclonal antibody conjugate MILGa (MIL-38/Gallium67) in patients with advanced prostate, bladder and pancreatic cancer

X
Trial Profile

MILGa-01: A first in human study to evaluate the safety and tolerability of monoclonal antibody conjugate MILGa (MIL-38/Gallium67) in patients with advanced prostate, bladder and pancreatic cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MILGa (Primary)
  • Indications Bladder cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Ureteral neoplasms; Urethral cancer
  • Focus Adverse reactions; First in man
  • Acronyms MILGa-01
  • Sponsors Minomic International
  • Most Recent Events

    • 16 Feb 2019 Results assessing outcomes of the miltuximab presented at the 2019 Genitourinary Cancers Symposium.
    • 16 Feb 2019 Status changed from recruiting to completed as per results presented at the 2019 Genitourinary Cancers Symposium.
    • 09 Apr 2018 Planned End Date changed from 27 Apr 2018 to 26 May 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top